Human Papillomavirus (HPV) seroprevalence, cervical HPV prevalence, genotype distribution and cytological lesions in solid organ transplant recipients and immunocompetent women in Sao Paulo, Brazil

Author(s):Show less -

Miyaji, Karina Takesaki ; Infante, Vanessa ; Picone, Camila de Melo ; Levi, Jose Eduardo ; Soares de Oliveira, Ana Carolina ; Lara, Amanda Nazareth ; Tacla, Maricy ; Dillner, Joakim ; Kann, Hanna ; Eklund, Carina ; Castanheira, Cristina Paula ; Mayaud, Philippe ; Christovam Sartori, Ana Marli ; Study Grp HPV Vaccine Immunosuppre

• Document type: Journal article
• Source: PLoS One; v. 17, n. 1, p. 12-pg., 2022-01-20.

Abstract

Introduction Solid organ transplant (SOT) recipients are at increased risk of Human Papillomavirus (HPV) persistent infection and disease. This study aimed to evaluate HPV seroprevalence, cervical HPV prevalence, genotype distribution, and frequency of HPV-related cervical lesions in SOT recipients in comparison to immunocompetent women. Methods Cross-sectional study including SOT and immunocompetent women aged 18 to 45 years who denied previous HPV-related lesions. Cervical samples were screened for HPV-DNA by a polymerase chain reaction (PCR)-based DNA microarray system (PapilloCheck (R)) and squamous intraepithelial lesions (SIL) by liquid-based cytology. A multiplexed pseudovirion-based serology assay (PsV-Luminex) was used to measure HPV serum antibodies. Results 125 SOT and 132 immunocompetent women were enrolled. Cervical samples were collected from 113 SOT and 127 immunocompetent women who had initiated sexual activity. HPV-DNA prevalence was higher in SOT than in immunocompetent women (29.6% vs. 20.2%, p = 0.112), but this difference was not statistically significant. High-risk (HR)-HPV was significantly more frequent in SOT than in immunocompetent women (19.4% vs. 7.9%, p = 0.014). Simultaneous infection with >= 2 HR-HPV types was found in 3.1% of SOT and 0.9% of immunocompetent women. HPV seropositivity for at least one HPV type was high in both groups: 63.8% of 105 SOT and 69.7% of 119 immunocompetent women (p = 0.524). Low-grade (LSIL) and high-grade SIL (HSIL) were significantly more frequent in SOT (9.7% and 5.3%, respectively) than in immunocompetent women (1.6% and 0.8%, respectively) (p= 0.001). Conclusions These results may reflect the increased risk of HPV persistent infection and disease progression in SOT women due to chronic immunosuppression. (AU)

• FAPESP's process: 16/06942-6 - Immunogenicity and safety of HPV vaccine in immunosuppressed women due to solid organ transplant and rheumatologic disease. Study 1: Evaluation of primary imune response to vaccination
• Grantee: Ana Marli Christovam Sartori
• Support Opportunities: Regular Research Grants